Trials in Philadelphia, Pennsylvania
Here are the top 6 medical studies for retinitis pigmentosa in Philadelphia, Pennsylvania
Popular Filters
Trials With No Placebo
4D-125 for Retinitis Pigmentosa
Recruiting1 awardPhase 1 & 2
New York, New York
This trial tests a new eye injection treatment for males with a genetic eye disease. The treatment replaces a faulty gene with a healthy one to help stop or slow down the disease. Gene therapy has been extensively studied and shows promise for treating genetic eye diseases by delivering functional genes to replace faulty ones.
Spatial Localization and Mapping (SLAM) and object recognition technology
Navigation System for Vision Impairment
Recruiting1 award7 criteria
Baltimore, Maryland
This trial tests a new technology that helps blind people navigate by creating a map of their surroundings and providing visual and sound cues. It targets legally blind individuals using the Argus II retinal prosthesis. The system helps users understand where they are and what objects are around them. The Argus II retinal prosthesis system has been developed to restore some vision to patients blind due to retinitis pigmentosa or outer retinal degeneration.
Phosphodiesterase Type 5 (PDE5) Inhibitor
Sildenafil for Choroidal Ischemia
Recruiting1 awardPhase 2
New York, New York
This trial is testing if Sildenafil can help patients with certain eye conditions by improving blood flow in the eye. The goal is to slow down vision loss and reduce the need for frequent treatments. Sildenafil, commonly known as Viagra, is primarily used to treat erectile dysfunction but has been studied for its effects on ocular blood flow and potential neuroprotective benefits in various eye conditions.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
Recruiting1 awardPhase 1 & 2
New York, New York
This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
Recruiting2 awardsPhase 1
Baltimore, Maryland
This trial is testing N-acetylcysteine (NAC) tablets to help people with Retinitis Pigmentosa (RP), a disease that causes vision loss. NAC is an antioxidant that protects eye cells from damage. The goal is to see if NAC can slow down or stop the progression of vision loss in RP patients.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.